Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Michelson

Showing results (321-330 of 339) with videos related to

Pageof 34
Sort By:
Mededportal : the Journal of Teaching and Learning Resources|March 14, 2020
Health Equity Rounds: An Interdisciplinary Case Conference to Address Implicit Bias and Structural Racism for Faculty and TraineesJoanna Perdomo, Destiny Tolliver, Heather Hsu, et al.
European Heart Journal|May 14, 2009
Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trialAlan D Michelson, Andrew L Frelinger, Eugene Braunwald, et al.
Journal of Thrombosis and Thrombolysis|July 20, 2020
Biomarkers of platelet activation and cardiovascular risk in the DAPT trialDavid D Berg, Robert W Yeh, Laura Mauri, et al.
Blood|July 31, 2015
Effects of eltrombopag on platelet count and platelet activation in Wiskott-Aldrich syndrome/X-linked thrombocytopeniaAnja J Gerrits, Emily A Leven, Andrew L Frelinger, et al.
Journal of the American College of Cardiology|July 26, 2014
Variability of individual platelet reactivity over time in patients treated with clopidogrel: insights from the ELEVATE-TIMI 56 trialWillibald Hochholzer, Christian T Ruff, Robert A Mesa, et al.
Blood|July 18, 2022
Ticagrelor vs placebo for the reduction of vaso-occlusive crises in pediatric sickle cell disease: the HESTIA3 studyMatthew M Heeney, Miguel R Abboud, Jessie Githanga, et al.
Lancet (London, England)|September 4, 2009
Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trialsMichelle L O'Donoghue, Eugene Braunwald, Elliott M Antman, et al.
Scientific Reports|May 15, 2024
Dysregulation of platelet serotonin, 14-3-3, and GPIX in sudden infant death syndromeAndrew L Frelinger, Robin L Haynes, Richard D Goldstein, et al.
Circulation|December 7, 2007
Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trialStephen D Wiviott, Dietmar Trenk, Andrew L Frelinger, et al.
Diabetologia|December 21, 2019
An exploratory, randomised, placebo-controlled, 14 day trial of the soluble guanylate cyclase stimulator praliciguat in participants with type 2 diabetes and hypertensionJohn P Hanrahan, Jelena P Seferovic, James D Wakefield, et al.
Pageof 34

Showing results (321-330 of 339) with videos related to

Sort By:
Pageof 34
Mededportal : the Journal of Teaching and Learning Resources|March 14, 2020
Health Equity Rounds: An Interdisciplinary Case Conference to Address Implicit Bias and Structural Racism for Faculty and TraineesJoanna Perdomo, Destiny Tolliver, Heather Hsu, et al.
European Heart Journal|May 14, 2009
Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trialAlan D Michelson, Andrew L Frelinger, Eugene Braunwald, et al.
Journal of Thrombosis and Thrombolysis|July 20, 2020
Biomarkers of platelet activation and cardiovascular risk in the DAPT trialDavid D Berg, Robert W Yeh, Laura Mauri, et al.
Blood|July 31, 2015
Effects of eltrombopag on platelet count and platelet activation in Wiskott-Aldrich syndrome/X-linked thrombocytopeniaAnja J Gerrits, Emily A Leven, Andrew L Frelinger, et al.
Journal of the American College of Cardiology|July 26, 2014
Variability of individual platelet reactivity over time in patients treated with clopidogrel: insights from the ELEVATE-TIMI 56 trialWillibald Hochholzer, Christian T Ruff, Robert A Mesa, et al.
Blood|July 18, 2022
Ticagrelor vs placebo for the reduction of vaso-occlusive crises in pediatric sickle cell disease: the HESTIA3 studyMatthew M Heeney, Miguel R Abboud, Jessie Githanga, et al.
Lancet (London, England)|September 4, 2009
Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trialsMichelle L O'Donoghue, Eugene Braunwald, Elliott M Antman, et al.
Scientific Reports|May 15, 2024
Dysregulation of platelet serotonin, 14-3-3, and GPIX in sudden infant death syndromeAndrew L Frelinger, Robin L Haynes, Richard D Goldstein, et al.
Circulation|December 7, 2007
Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trialStephen D Wiviott, Dietmar Trenk, Andrew L Frelinger, et al.
Diabetologia|December 21, 2019
An exploratory, randomised, placebo-controlled, 14 day trial of the soluble guanylate cyclase stimulator praliciguat in participants with type 2 diabetes and hypertensionJohn P Hanrahan, Jelena P Seferovic, James D Wakefield, et al.
Pageof 34